Save time and get answers to complex questions with AI chat
Dabrafenib and trametinib cost?Is guselkumab off patent in u s?Dabrafenib patent expiration date novartis gsk composition matter?What excipients are combined with ruxolitinib in apotex's medication?When will there be a generic loreev available?
See the DrugPatentWatch profile for Addyi
Addyi (flibanserin) is a prescription medication for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Its effect comes from changing neurotransmitter signaling in the brain, especially in the sexual desire pathways. Flibanserin acts as a serotonin receptor modulator and works on dopamine and norepinephrine signaling as well, helping rebalance brain chemicals involved in sexual desire.[1]
Flibanserin is described as: - A 5-HT1A receptor agonist - A 5-HT2A receptor antagonist These actions shift serotonin signaling in a way that is intended to increase sexual desire.[1]
No. Addyi is not an androgen/estrogen-type hormone therapy and it does not work like a direct “sexual stimulant” drug. Instead, it works through central (brain) neurotransmitter modulation—primarily by altering serotonin receptor activity and downstream effects on other neurotransmitters.[1]
Because it is designed to adjust brain neurotransmitter balance rather than produce an immediate effect, Addyi is taken on a daily schedule rather than as an as-needed medication.[1]
Other Questions About Addyi :